🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06793969
Recruiting Not applicable

Swartz Sheath With Angioplasty Guidewire-Assisted Technique for Patent Foramen Ovale Closure (STAGE-PFO)

NCT06793969 · tracked via the Priya Life Science China tracker
Sponsor
RenJi Hospital
Phase
Not applicable
Started
2023-12-24
Last updated
2025-01-27

Condition(s) studied

Patent Oval Foramen

Investigational drug(s) / intervention(s)

Swartz sheath with Angioplasty Guidewire-Assisted Technique for PFO tunnel passageConventional technique to pass the PFO tunnel

Swartz sheath with Angioplasty Guidewire-Assisted Technique for PFO tunnel passage: The angioplasty guidewire is advanced into the left atrium and left superior pulmonary vein (LSPV). The Swartz sheath is then delivered to the left atrium along the 0.014" guidewire through the PFO. Next, the Runthrough guidewire is changed to a 0.035" J-tipped guidewire, which is advanced into the LSPV. Finally, the delivery sheath for the PFO closure device is introduced to the left atrium along the guidewire, and all other toolkits are withdrawn.

Conventional technique to pass the PFO tunnel: In the conventional group, the PFO closure procedure is performed with a multi-functional catheter and guided by intraprocedural fluoroscopy and ICE

Study summary

The technical challenge in patent foramen ovale (PFO) closure lies in successfully establishing an occlusion pathway through the PFO tunnel using a guidewire or catheter. In this study, we aim to investigate the efficacy and safety of Swartz sheath with angioplasty guidewire-assisted technique for PFO Closure.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Aged between 18 and 65 * Confirmed diagnosis of PFO by transthoracic and transesophageal echocardiography * A history of cryptogenic stroke (CS) or transient ischemic attack (TIA) Exclusion Criteria: * Confirmed pregnancy * Confirmed diagnosis of intracardiac thrombosis * Confirmed diagnosis of pulmonary hypertension * Confirmed diagnosis of rheumatic heart disease, or valvular heart disease * Past medical history of myocardial infarction, unstable angina and intracranial hemorrhage

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Renji Hospital Shanghai China Recruiting

More RenJi Hospital trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06793969 on ClinicalTrials.gov ↗ ← All trials in China